Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
Am J Ophthalmol. 2013 Mar;155(3):438-447.e1. doi: 10.1016/j.ajo.2012.09.020. Epub 2012 Dec 4.
To evaluate the 5-year efficacy of photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV).
Retrospective study.
Forty-two eyes of 36 patients with PCV followed up for at least 60 months after PDT were reviewed. All eyes were primarily treated with PDT. Main outcome measure was best-corrected visual acuity (BCVA; logMAR [logarithm of minimal angle of resolution]) at baseline and at each follow-up visit. We also classified the eyes into 3 groups: improved (improvement ≥0.3 logMAR), decreased (deterioration ≥0.3 logMAR), and stable.
During the mean follow-up duration, 73.64 ± 13.47 months, the mean number of PDT was 2.21 ± 1.62 treatments. Recurrence was noted in 33 eyes (78.6%) during follow-up. The mean baseline BCVA was 0.78 ± 0.48 logMAR (20/120 Snellen equivalent), and the final BCVA at 60 months was 0.67 ± 0.52 logMAR (20/93 Snellen equivalent) (P = .050, paired t test). On the final evaluation at 60 months, the mean BCVA was improved in 14 eyes (33.3%), stable in 23 eyes (54.8%), and decreased in 5 eyes (11.9%).
At 60 months after initial PDT, 88.1% of PCV patients showed stable or improved BCVA after PDT. Despite a high recurrence rate, PDT remained effective for 5 years, and represents a good therapeutic approach to PCV.
评估光动力疗法（PDT）治疗息肉状脉络膜血管病变（PCV）患者的 5 年疗效。
回顾性研究。
回顾性分析了至少接受 PDT 治疗 60 个月的 36 例 42 只眼 PCV 患者的资料。所有患者均接受 PDT 作为初始治疗。主要观察指标为 PDT 治疗后基线时和每次随访时的最佳矫正视力（BCVA；logMAR [最小角分辨率对数]）。我们还将眼分为 3 组：改善（提高≥0.3 logMAR）、下降（下降≥0.3 logMAR）和稳定。
在平均 73.64±13.47 个月的随访期间，平均 PDT 治疗次数为 2.21±1.62 次。随访期间 33 只眼（78.6%）出现复发。基线时 BCVA 平均为 0.78±0.48 logMAR（20/120 视力表等价物），60 个月时的最终 BCVA 为 0.67±0.52 logMAR（20/93 视力表等价物）（P=0.050，配对 t 检验）。在 60 个月的最终评估时，14 只眼（33.3%）的平均 BCVA 改善，23 只眼（54.8%）稳定，5 只眼（11.9%）下降。
初始 PDT 后 60 个月，88.1%的 PCV 患者 PDT 后 BCVA 稳定或改善。尽管复发率较高，但 PDT 在 5 年内仍然有效，是治疗 PCV 的一种较好的治疗方法。
